List view / Grid view
21 April 2015 | By Victoria White
Results of the double-blind placebo-controlled Phase III trial demonstrating efficacy and safety of Raxone/Catena in patients with DMD have been published...
21 April 2015 | By Victoria White
ReNeuron has provided a further and final update on the PISCES Phase I clinical trial of its CTX stem cell therapy for disabled stroke patients...
20 April 2015 | By Victoria White
The first patient has been dosed in a Phase 1 clinical trial of CM-24, a first-in-class immunomodulatory mAb for the treatment of various types of cancers...
20 April 2015 | By Victoria White
Results from the randomised, pivotal Phase 3 study of KEYTRUDA versus ipilimumab in the treatment of unresectable advanced melanoma have been announced...
20 April 2015 | By Victoria White
Results are positive from a Phase II trial evaluating the Opdivo+Yervoy regimen versus Yervoy alone in patients with previously untreated advanced melanoma...
20 April 2015 | By Victoria White
The first presentation of data investigating the use of KEYTRUDA in 25 patients with advanced pleural mesothelioma was made at AACR 2015...
20 April 2015 | By Victoria White
TD2 and Navigating Cancer are teaming up to improve patient engagement in trials and bring patient-reported outcomes to the clinical trials process...
20 April 2015 | By Victoria White
New data from a Phase 1b study evaluating KEYTRUDA, in naïve and previously-treated patients with advanced NSCLC was presented at AACR 2015...
17 April 2015 | By Victoria White
The primary endpoint has been met in the pivotal clinical trial MS-SPI of MD1003 in the treatment of progressive multiple sclerosis...
17 April 2015 | By Victoria White
CheckMate -057, a Phase III study evaluating Opdivo in patients with advanced non-squamous non-small cell lung cancer (NSCLC), has stopped early...
17 April 2015 | By Victoria White
MedImmune has entered into a collaboration with Immunocore to conduct immuno-oncology combination trials in metastic melanoma...
17 April 2015 | By Victoria White
Latest data from the ongoing AURA study of AZD9291 demonstrated a median progression free survival of 13.5 months in patients with advanced EGFRm NSCLC...
17 April 2015 | By Trelleborg Sealing Solutions
For the first time at INTERPHEX (International Pharmaceutical Expo), in Booth 3816, Trelleborg Sealing Solutions will showcase its engineered innovations for medical, biotech & pharmaceutical applications in silicone and other elastomers...
16 April 2015 | By Victoria White
Targacept has announced TC-6499 did not meet the primary endpoint of a Phase 1/2 exploratory study as a treatment for diabetic gastroparesis...
16 April 2015 | By Victoria White
Cardio3 BioSciences, a leader in engineered cell therapies, has announced its intention to change its corporate name to 'Celyad'...
